UCLA UCLA Previously Published Works

Title

Outcomes of a 3-Year Quality Improvement Study to Improve Advance Care Planning in Patients With Decompensated Cirrhosis.

Permalink

https://escholarship.org/uc/item/8d14v1cc

Journal

American Journal of Gastroenterology, 119(3)

Authors

Patel, Arpan Bowman, Chip Prause, Nicole <u>et al.</u>

Publication Date

2023-12-11

DOI

10.14309/ajg.000000000002570

Peer reviewed

Open

Outcomes of a 3-Year Quality Improvement Study to Improve Advance Care Planning in Patients With Decompensated Cirrhosis

Arpan Patel, MD, PhD^{1,2}, Chip A. Bowman, MD³, Nicole Prause, PhD¹, Saikiran M. Kilaru, MD⁴, Andrew Nguyen, DO⁵, Nina Kogekar, MD⁶, Cynthia Cohen, MD⁷, Lindsay Channen, MD⁸, Alyson Harty, NP⁹, Ponni Perumalswami, MD¹⁰, Douglas Dietrich, MD⁹, Thomas Schiano, MD¹¹, Christopher Woodrell, MD, MS^{12,13} and Ritu Agarwal, MD⁹

Advance care planning in decompensated cirrhosis is recommended but rarely performed.

INTRODUCTION: To report outcomes of a 3-year quality improvement pilot study to improve advance directive (AD) completion.

- METHODS: The pilot consisted of champions, education, electronic health record templates, and workflow changes. We assessed changes, predictors, and effects of AD completion.
- RESULTS: The pilot led to greater (8.3%–36%) and earlier AD completion, particularly among those divorced, with alcohol-associated liver disease, and with higher Model of End-Stage Liver Disease–Sodium score. Decedents whose AD specified nonaggressive goals experienced lower hospital lengths of stay.
- DISCUSSION: Advance care planning initiatives are feasible and may reduce health care utilization among decedents requesting less aggressive care.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/AJG/D105

Am J Gastroenterol 2024;119:580-583. https://doi.org/10.14309/ajg.00000000002570

INTRODUCTION

Advance care planning (ACP) improves end-of-life (EOL) experience for seriously ill patients, but it is rarely performed for patients with decompensated cirrhosis (1,2). We previously reported 1-year results of a pilot quality improvement study, which improved advance directive (AD) completion rates over an 8-month period (3). In this study, we report final AD completion rates, predictors, and association with health care utilization among decedents, over a 3-year period.

METHODS

This pilot study was performed from November 1, 2018, to June 30, 2021, at a once-weekly hepatology clinic staffed by transplant hepatology fellows and attending hepatologists. The intervention consisted of a 1-hour education to clinic staff and fellows that included information about AD and ACP. Standardized electronic health record (EHR) templates were used to guide discussions.

Processes were created to facilitate availability, completion, and uploading of AD during clinic. We included all patients with decompensated cirrhosis, defined as a patient with cirrhosis and a history of a portal hypertension-related complication. Chart abstraction occurred between June 2018 and July 2021.

Measures

Our primary outcome was the presence of a completed AD in the EHR. AD included health care proxy forms, a living will, or a medical order for life-sustaining treatment, which included donot-resuscitate orders. Among decedents, we collected whether any limits to aggressive care (cardiopulmonary resuscitation, mechanical ventilation, dialysis, or artificial nutrition) were recorded. Other collected measures included age, gender, race/ ethnicity, insurance status, primary language, cause of cirrhosis, and Model of End-Stage Liver Disease–Sodium (MELD-Na) score. Among patients who died during the study period, we

¹Division of Digestive Diseases, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA; ²Department of Gastroenterology, Hepatology, and Nutrition, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA; ³Division of Digestive and Liver Diseases, Department of Medicine, Columbia University New York Presbyterian Hospital, New York, New York, USA; ⁴Division of Gastroenterology and Hepatology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA; ⁵Department of Gastroenterology and Hepatology, Kaiser Permanente Washington, Seattle, Washington, USA; ⁶Division of Gastroenterology, Montefiore Medical Center, Bronx, New York, USA; ⁷Division of Gastroenterology and Hepatology, Westchester Medical Center; ⁸Warren Alpert Medical School of Brown University in Providence, Providence, Rhode Island, USA; ⁹Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, USA; ¹⁰Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA; ¹¹Recanati Miller Transplant Institute, Mount Sinai Hospital, New York, New York, USA; ¹²Brookdale Department of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai, New York, USA; ¹³Geriatric Research, Education and Clinical Center, James J. Peters Veterans Affairs Medical Center, Bronx, New York, USA. **Correspondence:** Arpan Patel, MD, PhD. E-mail: ArpanPatel@mednet.ucla.edu. **Received June 7, 2023; accepted September 26, 2023; published online November 7, 2023**

Table 1. Characteristics and advance directive completion ratesfor patients receiving ACP intervention (N = 120)

Variable	N (%) or Mean (SD)
Female	46 (38.3%)
Race/ethnicity	
Hispanic or Latino	66 (55.0%)
White	12 (10.0%)
African American	18 (15.0%)
Asian	12 (10.0%)
Native/Hawaiian Islander	1 (0.8%)
Other	11 (9.2%)
Age	56.5 (11.8)
Insurance status	
Private	9 (7.5%)
Medicare	26 (21.7%)
Medicaid	83 (69.2%)
Not reported	2 (1.7%)
Marital status	
Divorced	14 (11.7%)
Married	46 (38.3%)
Never married	53 (44.2%)
Widowed	7 (5.8%)
Primary language	
English	80 (66.7%)
Spanish	28 (23.3%)
Mandarin	2 (1.7%)
Other	10 (8.3%)
Cause of cirrhosis	
Alcohol	50 (41.7%)
Autoimmune	4 (3.3%)
PBC or PSC	6 (5.0%)
Hepatitis B infection	5 (4.2%)
Hepatitis C infection	24 (20.0%)
MASLD	12 (10.0%)
Multiple	13 (10.8%)
Other	6 (5.0%)
MELD-Na score (most recent)	16.4 (8.8)
Decompensations	
Ascites/hydrothorax	107 (44.6%)
Variceal hemorrhage	49 (20.4%)
Encephalopathy	93 (38.8%)
Portopulmonary syndrome	1 (0.4%)
Hepatorenal syndrome	4 (1.7%)
Transplant status	
Denied	16 (13.3%)

Table 1. (continued)		
Variable	N (%) or Mean (SD)	
Evaluation ongoing	15 (12.5%)	
Listed	4 (3.3%)	
Never evaluated	85 (70.3%)	
Advanced directive type		
Health care proxy	40 (74.1%)	
MOLST or DNR order	12 (22.2%)	
Multiple	2 (3.7%)	
ACP, advance care planning; DNR, do-not-resuscitate; Model of End-Stage Liver Disease-Sodium; MELD-Na, MOLST, medical order for life-sustaining treatments; MASLD, metabolic dysfunction-associated steatotic liver disease;		

collected dates of hospitalizations, overall length of stay (LOS), and intensive care unit LOS. Data were collected and managed using REDCap (4).

PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis.

Statistical analysis

To identify predictors of completion, we used a general linear model for binomials. To understand the association between

Table 2. Significant predictors of advance directive completion

Predictor	В	P value
Age	0.02	0.24
Race/ethnicity (ref. Hispanic)		
Versus not Hispanic	-0.49	0.37
Primary insurance (ref. private)		
Medicare	-0.58	0.54
Medicaid	-0.26	0.75
Marital status (ref. married)		
Versus never married	0.39	0.43
Versus divorced	3.33	0.001
Versus widowed	-0.15	0.88
MELD-Na score	0.12	0.004
Primary language (ref. English)		
Spanish	0.70	0.28
Mandarin	0.14	0.93
Other language	0.63	0.46
Causes of cirrhosis (alcohol v. nonalcohol)	1.72	0.002
Presence of ascites/hydrothorax	0.79	0.33
Presence of variceal hemorrhage	-0.39	0.68
Presence of encephalopathy	-0.34	0.64
Bold terms indicate that the <i>P</i> -value <0.05. MELD-Na, MOLST, medical order for life-sustaining treatments.		

our quality improvement initiative and completion rates, we conducted a survival analysis using the R library survival (5). Baseline AD completion rate was assessed from time of earliest completed AD (March 20, 2012) to start of the intervention (November 1, 2018). This rate was then compared with AD completion rate during the intervention period up until the completion of the last AD (November 1, 2018, to March 25, 2021). Curves were compared using a log-rank test. Between-participant, signed rank tests were used to investigate whether the presence of an AD was associated with hospital and intensive care unit (ICU) LOS for decedents.

RESULTS

One hundred twenty patients were seen across 512 clinic visits, with an average of 4.3 visits per patient. Most of them were men, of Latino origin, English-speaking, and never married. The most common cause of cirrhosis was alcohol-associated liver disease (ALD) (41%), and the mean MELD-Na at first clinic visit was 16.4 (SD: 8.8). The most common decompensation was ascites and/or hepatic hydrothorax. Sixty-nine percent were never evaluated for liver transplantation (Table 1). AD completion

increased from 8.3% to 36%. Most were health care proxy forms (N = 40/54, 74%).

Patients who were divorced, compared with married (β = 3.33, *P* = .001), those with higher MELD-Na score, (β = 0.12, *P* = .004), and with diagnosis of ALD, compared with non-ALD (β = 1.72, *P* = .002) were more likely to complete an AD (Table 2). Patients seen during the intervention had less time from clinic visit to AD completion compared with those seen preintervention (χ^2 = 18.4, *P* < 0.001). The median time to AD's filed preintervention (median [SD]: 1,028 [SD: 931] days) was much longer than postintervention (246 [SD: 251] days) (Figure 1).

Of decedents (N = 20), 8 (40%) died in an acute care facility (see Figure, Supplementary Digital Content 1, http://links.lww. com/AJG/D105). Decedents had a median of 1 hospital visit lasting 11.5 days (SD = 26.2) and 0.5 ICU visits, lasting 6 days (SD = 7.0). Fifteen (75%) completed an AD, which were most often medical order for life-sustaining treatment (N = 10, 66.7%) forms. AD completion was associated with greater health care utilization at EOL, including higher hospital (median 13 vs 1 days, P < .001) and ICU (median 6.5 vs 0 days, P = .006) LOS.




Figure 1. Trends in advance directive completion over intervention period. *Represents patients who did not previously have an advance directive and were eligible for the intervention. ^Represents patients who had an advance directive uploaded before intervention. Time 0 is assumed to be the date that the first advance directive was uploaded in the electronic health record for this cohort. AD, advance directive.

However, of decedents with AD (N = 15), those requesting limits to care (N = 9) experienced lower hospital (median 13 vs 16 days, P < .001) and ICU (median 6.5 vs 9 days, P < .001) LOS.

DISCUSSION

Our ACP intervention—featuring provider education, provider champions, EHR documentation templates, and workflow changes—led to earlier and greater completion of AD. AD completion was highest among patients with higher MELD-Na scores, those with ALD, and those who were divorced. Completion was associated with longer hospital LOS at EOL but lower LOS among those who preferred limits to life-sustaining treatments.

Most completed AD focused on identifying surrogate decisionmakers, considered among the most important outcomes of ACP (6). That our intervention was more effective for groups that are likely to incur (high MELD-Na) and potentially require more support (divorced, patients with ALD) for complex medical decision-making suggests that future adaptations are needed.

The fact that AD completion was associated with longer hospital and ICU stays, but lower among decedents who requested less aggressive care, illustrates 2 important concepts. First, completion of AD, when specific, can be an important tool for ensuring goalconcordant care. Ideally, future ACP initiatives should focus on iterative discussions about goals, values, and preferences during clinic visits, which can promote and provide more helpful information in AD (7). This can be further promoted by formal, accessible communication skills training for trainees, and hepatology teams in ACP (8). Second, health care utilization as an outcome may not fully capture value. For instance, greater health care utilization may be aligned with a patient's wishes to receive aggressive care. Similarly, hospice utilization, which can avert costs, may not ultimately resonate with a patient's previous wishes. Future studies thus should include measures, such as quality of care and patient-reported outcomes (1,9).

Our study has several strengths. It was conducted at an urban center with a racially and ethnically diverse, economically underresourced population, which is critical given the significant disparities experienced in ACP by systemically disadvantaged and minoritized groups (10). It also incorporated the role of trainees to help guide improvement efforts. Our limitations include less potential to account for residual confounding from unobserved variables, presence of missing data outside our health system, assumption that clinic enrollment rates were steady over the study period, and lower generalizability to transplant centers. Notwithstanding, this is the first study to report sustainable improvement in AD documentation for the population with cirrhosis by addressing provider and system barriers.

CONFLICTS OF INTEREST

Guarantor of the article: Arpan Patel, MD, PhD.

Specific author contributions: A.P.: conceptualization,

methodology, data curation, writing-original draft, writing—review and editing. C.A.B.: data curation, writing-review and editing. N.P.: formal analysis, writing-original draft, writing-review and editing. S.M.K.: data curation, writing-review and editing. A.N.: data curation, writing-review and editing. N.K.: data curation, writing-review and editing. C.C.: data curation, writing-review and editing. L.C.: data curation, writing-review and editing. A.H.: data curation, writing-review and editing. P.P.: conceptualization, methodology, writing-review and editing. D.D.: data curation, writing-review and editing. C.W.: conceptualization, methodology, writing-review and editing. T.S.: conceptualization, methodology, writing-review and editing. R.A.: conceptualization, methodology, data curation, writing-review and editing.

Financial support: AASLD Transplant Hepatology Fellowship Award (AASLDF 50035) to A.P.

Potential competing interests: No conflicts of interest are declared. **Institutional review board:** The Mount Sinai Department of Medicine Quality Improvement committee approved this study as exempt for IRB Review.

REFERENCES

- McMahan RD, Tellez I, Sudore RL. Deconstructing the complexities of advance care planning outcomes: What do we know and where do we go? A scoping review. J Am Geriatr Soc 2021;69(1):234–44.
- Patel AA, Ryan GW, Tisnado D, et al. Deficits in advance care planning for patients with decompensated cirrhosis at liver transplant centers. JAMA Intern Med 2021;181(5):652–60.
- Patel A, Kogekar N, Agarwal R, et al. Improving advance care planning in outpatients with decompensated cirrhosis: A pilot study. J Pain Symptom Manage 2020;59(4):864–70.
- Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42(2):377–81.
- Terry M, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Springer: New York, NY, 2000. ISBN 0-387-98784-3.
- Sudore RL, Heyland DK, Lum HD, et al. Outcomes that define successful advance care planning: A Delphi panel consensus. J Pain Symptom Manage 2018;55(2):245–55.e8.
- Myers J, Steinberg L, Seow H. Controversies about advance care planning. JAMA 2022;327(7):684–5.
- 8. Back AL, Fromme EK, Meier DE. Training clinicians with communication skills needed to match medical treatments to patient values. J Am Geriatr Soc 2019;67(S2):S435–41.
- Ernecoff NC, Wessell KL, Bennett AV, et al. Measuring goal-concordant care in palliative care research. J Pain Symptom Manage 2021;62(3): e305–14.
- Rao JK, Anderson LA, Lin FC, et al. Completion of advance directives among U.S. consumers. Am J Prev Med 2014;46(1):65–70.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.